Roche Holding stock adds Alzheimer trial ahead of CTAD

Published on 11/11/2026 at 17:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock is entering a busy Alzheimer research period with a new Phase II program. CTAD will spotlight drugs and blood tests.

Roche's Alzheimer Pipeline Advances

Roche is preparing new Alzheimer drug and diagnostic data for the CTAD congress in Boston.
The TARBELA-AD study adds an oral neuroinflammation approach alongside Roche's amyloid-focused programs.
Investors will watch trial evidence, regulatory progress and commercial adoption as the pipeline develops.

Roche Holding, CH1499059983, Illustration mit AI erstellt.

Roche said on Tuesday, November 10, 2026, that it is starting a new Phase II Alzheimer study and will present a broad portfolio at the Clinical Trials on Alzheimer’s Disease congress in Boston. The company’s CTAD 2026 investor update adds specific presentation timings and outlines early safety data for RG6434.

Roche Holding stock traded at 435.68 euros on Lang & Schwarz at 17:42 CET on Wednesday, November 11, 2026.

New Trial Targets Neuroinflammation

The TARBELA-AD trial will assess the investigational oral NLRP3 inhibitor RG6434 in people with early symptomatic Alzheimer’s disease. Roche describes the study as randomized, double-blind and placebo-controlled, with neuroinflammation as a complementary target to amyloid biology.

The company will also present Phase I safety data from healthy participants for RG6434 during a scientific symposium on Tuesday, November 17, from 14:35 to 15:15 Eastern Time. The result is not yet evidence of efficacy: RG6434 remains investigational and the Phase II study is intended to test its efficacy and safety.

CTAD Sets Near-Term Milestones

Roche plans 16 accepted abstracts at CTAD from November 16 to November 19. The program includes updated Phase Ib/IIa Brainshuttle AD data for trontinemab on amyloid removal, biomarkers and brain delivery, while the Phase III PrevenTRON study has begun enrolling cognitively unimpaired participants with Alzheimer’s biomarkers.

Roche will also show clinical, health-economic and real-world analyses for its Elecsys pTau217 and pTau181 blood tests. Those presentations could help investors assess how the diagnostics portfolio may support earlier diagnosis and treatment decisions.

Pipeline Execution Remains Key

The new trial broadens Roche’s research strategy but does not yet establish a commercial contribution. Future trial results, regulatory decisions and adoption of medicines and diagnostic tests remain the main factors for the investment case.

Swiss equities provide the broader regional backdrop through the SMI.

See More news and analyses on Roche Holding stock.